When a company director writes a $500,000 check to buy shares, it's worth paying attention. The fact that Jenkins chose to join this public equity offering is a meaningful signal of confidence at the $125.00 price level -- which also happens to be higher than today’s stock price.The main target market comprises patients with serious and rare genetic dermatological conditions, with healthcare providers and specialty clinics as primary customers.The company operates a clinical-stage biopharmaceutical business ...